UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Pharma giants are sweating on the results of a federal government request for guidance on adding weight loss drugs to the ...

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...